U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. Science and Research Special Topics
  4. Advancing Regulatory Science
  5. Focus Areas of Regulatory Science Report
  6. Focus Area: Regenerative Medicine
  1. Focus Areas of Regulatory Science Report

Focus Area: Regenerative Medicine

Blood Cell Research Testing Lab
Stem Cell Possibilities Illustration
Bone Marrow Stem Cells Dividing

Importance to FDA

Regenerative medicine refers to a general approach to restore, replace, or recreate cells, tissues, or organs to treat or mitigate disease. The types of products that FDA regulates in this category include cell therapy, therapeutic tissue engineering products, any combination products using such therapies or products, some gene therapy products, and human cell and tissue products (except for those regulated solely under section 361 of the Public Health Service Act. Regulation of regenerative medicine therapies pose many challenges, some of which are listed below. FDA conducts research to improve and resolve challenges such as the lack of international consensus standards for regenerative product safety and effectiveness.

Examples

One example of a regenerative medicine therapy is a 3D-printed scaffold made of a new biomaterial with cells derived from allogeneic stem cells in vitro. Scaffolds allow multiple cell types to grow on a single implant to speed up tissue growth. This type of product raises scientific questions that affect regulatory evaluation and require evaluation by FDA researchers:

  • The use of allogeneic stem cells may present compatibility issues between the living tissue and the 3D-printed implant or an immune response, such as inflammation.
  • Product types cannot be sterilized in their final holding container (terminally sterilized), so it is a challenge to also assess sterility of the final product without compromising their structure and function.
  • Methods are needed to predict whether the differentiated cells will revert to stem cells or create tumors.
  • After implantation of this type of product, there are questions about whether the cells stay in place or migrate to other parts of the body where they may cause harm.
  • Physics-based quantitative modalities are needed to assess the quality of regenerated tissue during and after product remodeling upon implantation.
  • If the scaffold is designed to resorb (dissolve) at a rate proportional to cell proliferation, additional questions arise about the impact on scaffold structural integrity, biocompatibility of degradation products, cell survival and proliferation, and both structural and functional integrity of the regenerated tissue.

 

 

CROSS-CUTTING TOPICS

Minority Health and Health Equity Women’s Health Maternal Health Pediatric Health
Oncology Rare Diseases One Health Initiative  

 

EXPLORE THE FOCUS AREAS OF REGULATORY SCIENCE

Advanced Manufacturing Antimicrobial Resistance Artificial Intelligence Biomarkers
Complex Innovative Trial Design Digital Health Technologies Empowering Patients and Consumers to Make Better-Informed Decisions Food Safety
Increasing Access to Complex Generic Drug Products Individualized Therapeutics and Precision Medicine Medical Countermeasures and Preparedness for Emerging Infectious Diseases Microbiome Research
Model-Informed Product Development Novel Foods and Food Ingredients Novel Technologies to Improve Predictivity of Non-clinical Studies and Replace, Reduce, and Refine Reliance on Animal Testing Patient and Consumer Preferences and Perspectives
Patient-Reported Outcomes and other Clinical Outcome Assessments Product Safety Surveillance Quality of Compounded Drugs Regenerative Medicine
  Substance Use Disorders Technologies to Reduce Pathogen Contamination Use of Real-World Evidence to Support Biologic, Device, and Drug Development and Regulatory Decision-Making

 

Research Capabilities, Tools, and Resources

Research Management and Collaborations Technology Transfer and Public-Private Partnerships Physical Standards and Reference Materials Intramural Grant Programs Extramural Funding Mechanisms

Scientific Education, Training, and Communication

Fellowship and Training Opportunities Professional Development and Continuing Education Communication and External Meetings

Infrastructure

Facilities and Shared Resources Safety and Compliance

 

ADDITIONAL ORGANIZATIONAL INFORMATION

Office of the Chief Scientist

Office of Regulatory Science and Innovation

 Contact Us: FARS@fda.hhs.gov

 

Back to Top